Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846271 | 0.88 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL5845348 | 0.87 | CXCR2 (0.89) | CXCR2CXCR1KDM4E | |
| SCHEMBL5660669 | 0.86 | CXCR2 (0.76) | CXCR2CXCR1 | |
| SCHEMBL5846781 | 0.84 | CXCR2 (1.00) | CXCR2CXCR1KDM4E | |
| SCHEMBL3207238 | 0.83 | CXCR2 (0.75) | CXCR2CXCR1 | |
| SCHEMBL6850672 | 0.81 | CXCR2 (0.84) | CXCR2CXCR1 | |
| SCHEMBL5845566 | 0.80 | CXCR2 (0.81) | CXCR2CXCR1 | |
| SCHEMBL5845286 | 0.80 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL5845444 | 0.79 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL5847562 | 0.79 | CXCR2 (0.76) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151112-B1 | Pharmaceutical uses and synthesis of nicotinamides | UCB SA (GB) | 2006-12-19 | — | — | US | disclosed |
| US-7012099-B2 | Using substituted 4-amino-1- phenylbutan-2-ol compounds in form of their racemates, enantiomers, diastereoisomers or corresponding bases or corresponding salts of acids as regulators for the nociceptin/orphanin FQ ligands in drugs | GRUENENTHAL GMBH (DE) | 2006-03-14 | — | — | US | disclosed |
| US-6777432-B1 | TREATING A SUBJECT HAVING AN INFLAMMATORY DISORDER ALLEVIATED BY THE INHIBITION OF GRO- ALPHA CYTOKINES | DARWIN MOLECULAR CORPORATION | 2004-08-17 | — | — | US | disclosed |
| US-20030008859-A1 | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008859-A1 | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | OPRL1, OPRM1, OPRK1 | CXCR2 1520/4885CXCR1 2201/4885KDM4E 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.